We sit at the intersection of science and scalable manufacturing, offering a seamless pathway from concept to clinic for humanized antibodies. Explore our wider capabilities in Pharmaceutical Development & Manufacturing, Drug Substance Development, and Monoclonal Antibody Development.
Strategic Overview of Humanized Antibody Development
Humanization reconciles the high affinity of murine or alternative species antibodies with the low immunogenicity required for human administration. We engineer complementarity-determining regions (CDRs) into optimized human frameworks, confirm structural integrity in silico, and iteratively refine variants for manufacturability, stability, and regulatory alignment. Early focus on developability—aggregation propensity, post-translational liabilities, and charge heterogeneity—prevents expensive re-work downstream. Continuous analytics, risk-driven comparability protocols, and data-rich decision gates keep timelines predictable while meeting global cGMP requirements.
Our Humanized Antibody Development Services
Before detailing individual offerings, we note that every program benefits from an integrated project team covering molecular design, upstream and downstream process science, analytical development, and quality affairs. Modular entry points allow clients to engage at any stage, yet the majority select our full-spectrum package to minimize tech-transfer friction.
Target Epitope Mapping Service
We deploy high-resolution epitope binning, hydrogen–deuterium exchange mass spectrometry, and computational surface scanning to define antigenic hot spots. Precision mapping de-risks CDR grafting by ensuring the retained paratope preserves critical contact residues. Differential binding kinetics across isoforms, mutants, and orthologs guide subsequent liability screens and manufacturability filters.
CDR Grafting & Framework Selection Service
Our bioinformatics platform cross-references many human germline sequences, selecting frameworks that balance structural homology with expression robustness. We execute iterative back-mutations to recover affinity, employ de-novo loop modelling to eliminate steric clashes, and validate final constructs via molecular dynamics. This service shortens lead optimization while complying with ICH Q6B expectations for primary-sequence comparability.
Expression Vector Engineering Service
Optimized humanized variable regions are cloned into proprietary dual-promoter vectors supporting amplified transcriptional control. We incorporate signal-peptide libraries, secretion-enhancement tags, and synthetic introns to maximize transient or stable productivity in CHO and HEK platforms. Marker-free selection reduces regulatory burden, while built-in barcode sequences accelerate clone traceability during master cell bank (MCB) qualification.
Cell Line & Upstream Process Development Service
High-throughput cloning is followed by single-cell imaging and fed-batch micro-bioreactor screening to identify clones with favorable critical quality attributes (CQA) profiles. We iterate feeding strategies—amino acid balancing, dynamic osmolality, trace-metal supplementation—to drive titers while preserving glycan uniformity. Scalability is demonstrated through 3 L, 50 L, and 200 L geometrically similar bioreactors.
Analytical Characterization & Developability Assessment Service
Orthogonal techniques—capillary electrophoresis, LC-MS peptide mapping, mass photometry, and differential scanning calorimetry—build a fingerprint database for every lead. Early-stage forced-degradation panels simulate pH, thermal, and oxidative stress, revealing liabilities long before clinical material is required. Results feed our predictive algorithms for viscosity, isoelectric point, and aggregation risk, informing formulation choices and regulatory CMC narratives.
cGMP Drug Substance Manufacturing Service
Humanized antibody drug substance production proceeds under EMA and FDA-inspected quality systems. Disposable flow-through clarification and continuous Protein A chromatography compress cycle times while maintaining viral clearance margins. Real-time release analytics integrate multi-attribute LC-MS and in-line spectroscopic monitoring, enabling parametric release where accepted. Clients receive DS in scalable presentation formats—bulk frozen bags, single-use bottles, or lyophilized cake—accompanied by a regulatory-ready documentation package.
We fuse state-of-the-art molecular design with robust cGMP manufacturing to deliver humanized antibodies that are commercially viable. Reach out to align your innovation with our proven development engine.
Our products and services are for research use only.
